23 hours ago We offer vaccination appointments at several convenient locations throughout the Nashville area. Learn more at 'VUMC Get Vaccinated' and schedule yours today. Pay as Guest. If you do not have a My Health account, you can Click Here to pay your bill. >> Go To The Portal
We offer vaccination appointments at several convenient locations throughout the Nashville area. Learn more at 'VUMC Get Vaccinated' and schedule yours today. Pay as Guest. If you do not have a My Health account, you can Click Here to pay your bill.
Vanderbilt-Ingram Cancer Center is a leader in the prevention, diagnosis and treatment of cancer. The center's world-renowned team of experts provides an integrated, personalized and patient-centered approach to cancer care, including treatment, research, support, education and outreach.
Feb 09, 2021 · Nashville, Tennessee. Main: (615) 936-8422. Visit Website. Exit Disclaimer. Vanderbilt-Ingram Cancer Center is a matrix center that integrates all of Vanderbilt’s cancer-related expertise and resources to alleviate cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention ...
1:438:41How to use a patient portal - YouTubeYouTubeStart of suggested clipEnd of suggested clipYou access the portal through your medical center's website the portal website or you can save it asMoreYou access the portal through your medical center's website the portal website or you can save it as a favorite to your device. From my medical center's.
If you're a new patient, you can sign up during your first visit. To schedule a visit, call us at (615) 322-5000 or go to any of our Vanderbilt walk-in clinics. If you're signing up on behalf of someone else, you'll need to provide us with your power of attorney.
My Health at Vanderbilt (MHAV) is an electronic health record portal developed for patients of Vanderbilt University Medical Center (VUMC). Services and content provided by My Health at Vanderbilt are available to users who are over 18 or their authorized representatives.
You can complete the application at the child's next appointment, or download, print and complete the form below: "My Health at Vanderbilt Account Access for Children 13-17." Bring it with you to your child's next appointment. Ensure your child signs the application as well.
Each year Vanderbilt awards merit-based scholarships to applicants who demonstrate exceptional accomplishment and intellectual promise.
Vanderbilt was the only Tennessee hospital to be nationally ranked by number in U.S. News and World Report's 2019-2020 Best Hospitals Rankings. It ranked No. 9 in the nation for nephrology; No. 18 for urology; No.Jul 30, 2019
Vanderbilt-Ingram Cancer Center is a matrix center that integrates all of Vanderbilt’s cancer-related expertise and resources to alleviate cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education, and community initiatives. Vanderbilt-Ingram was founded in 1993 and became an NCI-Designated Cancer Center in 1995 and a comprehensive cancer center in 2001.
Vanderbilt-Ingram’s goal is to implement research initiatives with the most significant potential to impact cancer prevention, detection, diagnosis, and treatment by leveraging the center’s strong culture of transdisciplinary collaboration. This culture is exemplified by several NCI-funded grants, including two NCI Specialized Programs of Research Excellence in breast cancer and gastrointestinal cancer; a long-standing partnership with Meharry Medical College and Tennessee State University to reduce cancer health disparities; the Southern Community Cohort Study, one of the largest and most intensive collaborative studies ever launched to evaluate the determinants of cancer among African Americans and low-income adults regardless of race; and the Cancer Systems Biology Consortium focused on small cell lung cancer.
The National Cancer Institute (NCI) designates us as a Comprehensive Cancer Center, the highest ranking by the world’s leading authority on cancer. We are the only one in Tennessee that conducts research and cares for adults and children with cancer. National Comprehensive Cancer Network.
When the diagnosis is cancer, you want everything to be just right: the right team of experts around you, providing you with the right diagnosis, the right treatment, at the right time.
Cancer care requires the expertise of specialists in many disciplines, from surgeons and pathologists to medical and radiation oncologists. Here, you’ll receive personalized treatment recommendations from all areas, including radiation therapy, cancer medicines, surgery and even clinical trials. Specialized tumor boards.
Recognized cancer care: The National Cancer Institute designates Vanderbilt-Ingram Cancer Center as a Comprehensive Cancer Center, the highest ranking by the world’s leading authority on cancer.
Vanderbilt-Ingram Cancer Center at Wilson Co. *#N#1411 West Baddour Parkway#N#Lebanon, TN. 37087
Aetna Better Health Transplants (Kentucky Medicaid. Requires single case agreement)
BCBST CoverKids – (Under age 19 Adults patients may require preauthorization.)
Cigna Connect (expanding from Nashville market to all TN markets beginning 2021.)
David Cella, PhD, is Associate Director for Prevention and Control at Robert Lurie Comprehensive Cancer Center and Chair of the Department of Medical School Sciences, and Director, Institute for Public Health and Medicine – Center for Patient Centered Outcomes at Northwestern University. Dr. Cella’s career has focused on studying questions regarding quality of life measurement in clinical trials, cross-cultural equivalence of quality of life measurement, efficacy of psychosocial interventions in oncology, and medical outcomes research.
Moses Chair in Cancer Research; Director, Vanderbilt Center for Quantitative Sciences; Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD); Associate Director for Quantitative Sciences Integration, VICC. Professor and Chair, Department of Biostatistics; and Professor of Biomedical Informatics and Health Policy. Dr. Shyr has developed biostatistical and bioinformatic methodologies for clinical trial design, high-dimensional data preprocessing, estimating relative potency in a parallel line bioassay, and other statistical and bioinformatic approaches.
Corey Casper, MD, MPH, is the President and Chief Executive Officer at IDRI, a non-profit global health biotechnology organization whose mission is the eradication of infectious disease and cancer in low- and middle-income countries. Dr.
James DeGregori, PhD, is a Professor in the Department of Biochemistry and Molecular Genetics (faculty since 1997) and Deputy Director of the University of Colorado Cancer Center. He holds the Courtenay and Lucy Patten Davis Endowed Chair in Lung Cancer Research. His lab seeks to understand how aging and other carcinogenic conditions promote cancer evolution and to discover pathway dependencies in cancers that can be exploited therapeutically. His lab studies the evolution of cancer, in the context of their Adaptive Oncogenesis model, with a focus on how aging, smoking, Down Syndrome, and other insults influence cancer initiation and responses to therapy. The lab has developed this cancer model based on classic evolutionary principles, and substantiated this model by theoretical, experimental and computational studies.
Dexter Frederick, MD, is the Founder and Executive Director of Brain Expansions Scholastic Training (BEST) Foundation. BEST helps minority students prepare confidently for careers in health care. By exposing middle school and high school students to different health care careers, the program aims to inspire them to pursue college degrees.
Elizabeth Platz, MPH, ScD, is Professor of Epidemiology in the Cancer Epidemiology Track at the Johns Hopkins Bloomberg School of Public Health and Co-Leader of the Cancer Prevention and Control Program at the SKCCC. With a research focus on the molecular and genetic epidemiology of prostate and colon cancers that incorporates health disparities and strives toward translation of findings, her expertise complements the full spectrum of Aims of the Cancer Epidemiology Program.
Charlie Rudin, MD, PhD, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials. He is Chief, Thoracic Oncology Service; Co-Director, Druckenmiller Center for Lung Cancer Research; and Sylvia Hassenfeld Chair in Lung Cancer Research at Memorial Sloan Kettering.